AstraZeneca has not been among the most successful big pharma companies in recent years. First-quarter revenue this year slipped 12%, while income and EPS fell 21% compared to the year-ago period. What's the reason? The company lost patent protection for Seroquel, Atacand, and Crestor with few immediate options to replace the lost sales, which will heighten the scrutiny for each pipeline move in the short term.
In that regard, the company has a fair showing in the pipeline, including several ongoing attempts to expand indications for drugs already on the market. But it also lacks the "wow" factor for novelty. Hitting it big like its big pharma peers will require taking some big leaps. Luckily, a recent partnership with the University of Manchester Paterson Institute for Cancer Research offers all of the above. Fool contributor Maxx Chatsko breaks down the implications in the following video.
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article AstraZeneca's Refreshingly New Cancer Pact originally appeared on Fool.com.
Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.